Centogene Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Centogene.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Healthcare earnings growth | 21.0% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 19 Jan 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 60 | -45 | N/A | N/A | 1 |
12/31/2023 | 49 | -36 | -34 | -32 | N/A |
9/30/2023 | 50 | -38 | -32 | -29 | N/A |
6/30/2023 | 51 | -40 | -29 | -26 | N/A |
3/31/2023 | 49 | -40 | -27 | -24 | N/A |
12/31/2022 | 47 | -39 | -29 | -26 | N/A |
9/30/2022 | -15 | -44 | -29 | -28 | N/A |
6/30/2022 | 2 | -58 | -31 | -29 | N/A |
3/31/2022 | 190 | -44 | -34 | -32 | N/A |
12/31/2021 | 42 | -57 | -27 | -22 | N/A |
9/30/2021 | 162 | -40 | 3 | 13 | N/A |
6/30/2021 | 168 | -24 | 1 | 15 | N/A |
3/31/2021 | 126 | -27 | -5 | 13 | N/A |
1/1/2021 | 38 | -60 | -8 | 8 | N/A |
9/30/2020 | 73 | -30 | -36 | -24 | N/A |
6/30/2020 | 49 | -28 | -31 | -21 | N/A |
3/31/2020 | 50 | -24 | -17 | -9 | N/A |
12/31/2019 | 49 | -21 | -15 | -8 | N/A |
9/30/2019 | 44 | -19 | -13 | -4 | N/A |
6/30/2019 | 45 | -16 | -11 | -3 | N/A |
3/31/2019 | 43 | -13 | -16 | -6 | N/A |
12/31/2018 | 40 | -11 | -16 | -5 | N/A |
9/30/2018 | 39 | -9 | -21 | -4 | N/A |
12/31/2017 | 32 | -5 | -22 | -4 | N/A |
12/31/2016 | 28 | -5 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 39K's forecast earnings growth is above the savings rate (0.7%).
Earnings vs Market: Insufficient data to determine if 39K's earnings are forecast to grow faster than the German market
High Growth Earnings: Insufficient data to determine if 39K's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 39K's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 39K's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 39K's Return on Equity is forecast to be high in 3 years time